{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T08:29:26Z","timestamp":1768292966380,"version":"3.49.0"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,13]],"date-time":"2022-09-13T00:00:00Z","timestamp":1663027200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100014382","name":"Ipsen Pharma SA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014382","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.ctrv.2022.102453","type":"journal-article","created":{"date-parts":[[2022,8,10]],"date-time":"2022-08-10T17:36:30Z","timestamp":1660152990000},"page":"102453","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Cabozantinib after prior checkpoint inhibitor therapy in patients with solid tumors: A systematic literature review"],"prefix":"10.1016","volume":"110","author":[{"given":"Jeffrey","family":"Graham","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arndt","family":"Vogel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ann-Lii","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georg A.","family":"Bjarnason","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joel W.","family":"Neal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.ctrv.2022.102453_b0005","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1016\/j.ctrv.2022.102453_b0010","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1104621","article-title":"Ipilimumab plus dacarbazine for previously untreated metastatic melanoma","volume":"364","author":"Robert","year":"2011","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ctrv.2022.102453_b0015","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s40425-018-0316-z","article-title":"Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations","volume":"6","author":"Gong","year":"2018","journal-title":"J Immunother Cancer"},{"issue":"1","key":"10.1016\/j.ctrv.2022.102453_b0020","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1093\/annonc\/mdx686","article-title":"Mechanistic overview of immune checkpoints to support the rational design of their combinations in cancer immunotherapy","volume":"29","author":"Rotte","year":"2018","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.ctrv.2022.102453_b0025","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.3390\/ijms21072531","article-title":"Current insights into combination therapies with MAPK inhibitors and immune checkpoint blockade","volume":"21","author":"Shin","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ctrv.2022.102453_b0030","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/s13045-020-00977-0","article-title":"Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001\u20132020)","volume":"13","author":"Huang","year":"2020","journal-title":"J Hematol Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2022.102453_b0035","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s13045-019-0718-5","article-title":"Recent advances on anti-angiogenesis receptor tyrosine kinase inhibitors in cancer therapy","volume":"12","author":"Qin","year":"2019","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.ctrv.2022.102453_b0040","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.ctrv.2018.07.009","article-title":"Current and emerging therapies for first-line treatment of metastatic clear cell renal cell carcinoma","volume":"70","author":"Atkins","year":"2018","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ctrv.2022.102453_b0045","unstructured":"Ipsen Pharma. Cabometyx (cabozantinib) [summary of product characteristics]. European Medicines Agency. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/cabometyx-epar-product-information_en.pdf (Accessed 5 May 2022)."},{"key":"10.1016\/j.ctrv.2022.102453_b0050","unstructured":"European Medicines Agency. Summary of opinion (post authorisation): Cabometyx (cabozantinib). https:\/\/www.ema.europa.eu\/en\/documents\/smop\/chmp-post-authorisation-summary-opinion-cabometyx-ii-23_en.pdf (Accessed May 5, 2022)."},{"issue":"29","key":"10.1016\/j.ctrv.2022.102453_b0055","doi-asserted-by":"crossref","first-page":"3639","DOI":"10.1200\/JCO.2012.48.4659","article-title":"Cabozantinib in progressive medullary thyroid cancer","volume":"31","author":"Elisei","year":"2013","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.ctrv.2022.102453_b0060","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.1093\/annonc\/mdx479","article-title":"Overall survival analysis of EXAM, a phase III trial of cabozantinib in patients with radiographically progressive medullary thyroid carcinoma","volume":"28","author":"Schlumberger","year":"2017","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.ctrv.2022.102453_b0065","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/S1470-2045(21)00332-6","article-title":"Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"22","author":"Brose","year":"2021","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.ctrv.2022.102453_b0070","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/S1470-2045(16)30107-3","article-title":"Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial","volume":"17","author":"Choueiri","year":"2016","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.ctrv.2022.102453_b0075","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa2026982","article-title":"Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma","volume":"384","author":"Choueiri","year":"2021","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.ctrv.2022.102453_b0080","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1200\/JCO.2016.70.7398","article-title":"Cabozantinib versus sunitinib as initial targeted therapy for patients with metastatic renal cell carcinoma of poor or intermediate risk: the Alliance A031203 CABOSUN trial","volume":"35","author":"Choueiri","year":"2017","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2022.102453_b0085","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1056\/NEJMoa1717002","article-title":"Cabozantinib in patients with advanced and progressing hepatocellular carcinoma","volume":"379","author":"Abou-Alfa","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2022.102453_b0090","unstructured":"National Institute for Health Research. International prospective register of systematic reviews. https:\/\/www.crd.york.ac.uk\/PROSPERO\/ (Accessed May 20, 2021)."},{"key":"10.1016\/j.ctrv.2022.102453_b0095","unstructured":"PRISMA. Transparent reporting of systematic reviews and meta-analyses. http:\/\/www.prisma-statement.org\/ (Accessed May 20, 2021)."},{"key":"10.1016\/j.ctrv.2022.102453_b0100","unstructured":"BMJ Best Practice. What is GRADE? https:\/\/bestpractice.bmj.com\/info\/toolkit\/learn-ebm\/what-is-grade\/ (Accessed January 13, 2022)."},{"issue":"7650","key":"10.1016\/j.ctrv.2022.102453_b0105","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.ctrv.2022.102453_b0110","unstructured":"Wells GA, Shea B, O'Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. https:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp (Accessed May 20, 2021)."},{"issue":"15_suppl","key":"10.1016\/j.ctrv.2022.102453_b0115","doi-asserted-by":"crossref","first-page":"4514","DOI":"10.1200\/JCO.2021.39.15_suppl.4514","article-title":"Outcomes of patients who progressed while receiving avelumab + axitinib (A + Ax) and received subsequent treatment (Tx) in JAVELIN Renal 101","volume":"39","author":"Albiges","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2022.102453_b0120","first-page":"S26","article-title":"Improved response rate of cabozantinib after immune checkpoint therapy in patients with metastatic renal cell carcinoma","volume":"4","author":"Alves Costa Silva","year":"2020","journal-title":"Kidney Cancer"},{"issue":"2","key":"10.1016\/j.ctrv.2022.102453_b0125","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/s41416-018-0104-z","article-title":"The efficacy of VEGFR TKI therapy after progression on immune combination therapy in metastatic renal cell carcinoma","volume":"119","author":"Barata","year":"2018","journal-title":"Br J Cancer"},{"issue":"suppl 5","key":"10.1016\/j.ctrv.2022.102453_b0130","doi-asserted-by":"crossref","first-page":"v309","DOI":"10.1093\/annonc\/mdx371.030","article-title":"Efficacy of cabozantinib (C) after PD-1\/PD-L1 checkpoint inhibitors in metastatic renal cell carcinoma (mRCC): the Gustave Roussy experience (876P)","volume":"28","author":"Derosa","year":"2017","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.ctrv.2022.102453_b0135","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1002\/cam4.3717","article-title":"Cabozantinib real-world effectiveness in the first-through fourth-line settings for the treatment of metastatic renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium","volume":"10","author":"Gan","year":"2021","journal-title":"Cancer Med"},{"key":"10.1016\/j.ctrv.2022.102453_b0140","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.ejca.2020.09.030","article-title":"Real-world evidence of cabozantinib in patients with metastatic renal cell carcinoma: Results from the CABOREAL Early Access Program","volume":"142","author":"Albiges","year":"2021","journal-title":"Eur J Cancer"},{"issue":"4","key":"10.1016\/j.ctrv.2022.102453_b0145","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s11523-020-00732-y","article-title":"Cabozantinib after a previous immune checkpoint inhibitor in metastatic renal cell carcinoma: a retrospective multi-institutional analysis","volume":"15","author":"Iacovelli","year":"2020","journal-title":"Target Oncol"},{"issue":"15_suppl","key":"10.1016\/j.ctrv.2022.102453_b0150","doi-asserted-by":"crossref","first-page":"4544","DOI":"10.1200\/JCO.2021.39.15_suppl.4544","article-title":"Phase I\/II trial of pembrolizumab and cabozantinib in the treatment of metastatic renal cell carcinoma (mRCC)","volume":"39","author":"Kessler","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2022.102453_b0155","first-page":"S16","article-title":"Combination cabozantinib and nivolumab treatment in patients with refractory metastatic renal cell carcinoma (mRCC)","author":"Kinsey","year":"2019","journal-title":"Eighteenth International Kidney Cancer Symposium"},{"issue":"6_suppl","key":"10.1016\/j.ctrv.2022.102453_b0160","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1200\/JCO.2018.36.6_suppl.684","article-title":"Real-world experience with cabozantinib in metastatic clear cell renal cell carcinoma (mccRCC) (684)","volume":"36","author":"Lemke","year":"2018","journal-title":"J Clin Oncol"},{"issue":"6_suppl","key":"10.1016\/j.ctrv.2022.102453_b0165","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1200\/JCO.2021.39.6_suppl.293","article-title":"Cabozantinib versus other TKIs after CPI treatment in the real-world management of patients with metastatic renal cell carcinoma (mRCC)","volume":"39","author":"Marteau","year":"2021","journal-title":"J Clin Oncol"},{"issue":"suppl 8","key":"10.1016\/j.ctrv.2022.102453_b0170","doi-asserted-by":"crossref","first-page":"viii311","DOI":"10.1093\/annonc\/mdy283.088","article-title":"Activity of cabozantinib (cabo) after PD-1\/PD-L1 immune checkpoint blockade (ICB) in metastatic clear cell renal cell carcinoma (mccRCC) (879P)","volume":"29","author":"McGregor","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2022.102453_b0175","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.ejca.2020.05.009","article-title":"Activity of cabozantinib after immune checkpoint blockade in metastatic clear-cell renal cell carcinoma","volume":"135","author":"McGregor","year":"2020","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2022.102453_b0180","article-title":"Cabozantinib in combination with atezolizumab in NSCLC patients previously treated with an immune checkpoint inhibitor: results from cohort 7 of the COSMIC-021 study (oral presentation)","author":"Neal","year":"2021","journal-title":"Singapore"},{"issue":"6","key":"10.1016\/j.ctrv.2022.102453_b0185","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/s41416-018-0164-0","article-title":"Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma","volume":"119","author":"Powles","year":"2018","journal-title":"Br J Cancer"},{"issue":"15_suppl","key":"10.1016\/j.ctrv.2022.102453_b0190","doi-asserted-by":"crossref","first-page":"4569","DOI":"10.1200\/JCO.2021.39.15_suppl.4569","article-title":"A phase 2 single-arm study of cabozantinib in patients with advanced or unresectable renal cell carcinoma pretreated with one immune checkpoint inhibitor: the BREAKPOINT trial (MeetUro trial 03-NCT03463681)","volume":"39","author":"Procopio","year":"2021","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ctrv.2022.102453_b0195","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1097\/COC.0000000000000791","article-title":"Clinical outcomes of metastatic renal carcinoma following disease progression to programmed death (PD)-1 or PD-L1 inhibitors (IO): a Meet-URO Group Real World Study (Meet-Uro 7)","volume":"44","author":"Santini","year":"2021","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.ctrv.2022.102453_b0200","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.ejca.2019.04.003","article-title":"Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with second-line VEGFR-TKI after first-line immune checkpoint inhibitors","volume":"114","author":"Shah","year":"2019","journal-title":"Eur J Cancer"},{"issue":"9","key":"10.1016\/j.ctrv.2022.102453_b0205","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.3390\/cancers13092002","article-title":"The use of cabozantinib in advanced hepatocellular carcinoma in Hong Kong\u2013a territory-wide cohort study","volume":"13","author":"Wong","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"suppl 1","key":"10.1016\/j.ctrv.2022.102453_b0210","doi-asserted-by":"crossref","first-page":"S187","DOI":"10.1016\/S0959-8049(17)30678-0","article-title":"Overall survival results from the phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma (METEOR)","volume":"72","author":"Schmidinger","year":"2017","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.ctrv.2022.102453_b0215","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3233\/KCA-210110","article-title":"Real-word experience of cabozantinib in metastatic renal cell carcinoma (mRCC): results from the Canadian Kidney Cancer information system (CKCis)","volume":"5","author":"Zhang","year":"2021","journal-title":"Kidney Cancer"},{"issue":"7","key":"10.1016\/j.ctrv.2022.102453_b0220","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1158\/1078-0432.CCR-21-3726","article-title":"Cabozantinib plus nivolumab phase I expansion study in patients with metastatic urothelial carcinoma refractory to immune checkpoint inhibitor therapy","volume":"28","author":"Girardi","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"15_suppl","key":"10.1016\/j.ctrv.2022.102453_b0225","doi-asserted-by":"crossref","first-page":"5037","DOI":"10.1200\/JCO.2020.38.15_suppl.5037","article-title":"Phase I expansion study of cabozantinib plus nivolumab (CaboNivo) in metastatic urothelial carcinoma (mUC) patients (pts) with progressive disease following immune checkpoint inhibitor (ICI) therapy","volume":"38","author":"Girardi","year":"2020","journal-title":"J Clin Oncol"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737222001220?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737222001220?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T09:27:40Z","timestamp":1759656460000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737222001220"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":45,"alternative-id":["S0305737222001220"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2022.102453","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cabozantinib after prior checkpoint inhibitor therapy in patients with solid tumors: A systematic literature review","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2022.102453","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102453"}}